Eisai Inc. Announces Non-Exclusive Licensing Agreement with Generic Drug
Manufacturer to Provide Generic Version of donepezil HCl 23 mg
WOODCLIFF LAKE, N.J., Aug. 29, 2013
WOODCLIFF LAKE, N.J., Aug. 29, 2013 /PRNewswire/ --Eisai Inc. announced that
the company has recently entered into a non-exclusive licensing agreement in
the United States with a manufacturer of generic pharmaceuticals that grants
certain rights, including the right to market and offer for sale a generic
version of donepezil hydrochloride 23 mg and a non-exclusive license to Eisai
Intellectual Property covering donepezil hydrochloride 23 mg, including U.S.
Patent No. 8,481,565. This agreement applies to the United States only.
About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to
patients and their families, and helping to increase the benefits health care
provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co.,
Ltd., our passionate commitment to patient care is the driving force behind
our efforts to help address unmet medical needs. We are a fully integrated
pharmaceutical business with discovery, clinical, manufacturing and marketing
capabilities. Our key areas of commercial focus include oncology and specialty
care (Alzheimer's disease, epilepsy and metabolic disorders).To learn more
about Eisai Inc., please visit us at www.eisai.com/US.
Eisai Inc. has affiliates that are part of a global product creation
organization that includes R&D facilities in Massachusetts, New Jersey, North
Carolina and Pennsylvania, as well as a global demand chain organization that
includes manufacturing facilities in Maryland and North Carolina. Eisai's
global areas of R&D focus include neuroscience; oncology; metabolic disorders;
vascular, inflammatory and immunological reaction; and antibody-based
Media Inquiries Investor Inquiries
Marcia Diljak Alex Scott
Eisai Inc. Eisai Inc.
(201) 746-2236 (201) 746-2177
SOURCE Eisai Inc.
Press spacebar to pause and continue. Press esc to stop.